Biocompatible protein compositions of invertible phase

专利摘要:

公开号:ES2544962T9
申请号:ES08856256.6T
申请日:2008-12-02
公开日:2016-03-08
发明作者:Ronald Dieck；Ian J. Handley；Neil Winterbottom；Joanna Wang
申请人:Tenaxis Medical Inc；
IPC主号:

专利说明:

DESCRIPTION
Biocompatible protein compositions of invertible phase 5 INTRODUCTION
[0001] A number of sealant compositions have become available to control fluid leakage in a surgical location, as well as for other applications. However, currently available sealant compositions may suffer serious limitations with respect to the field in which they can be used, as well as their
10 biocompatibility and its physical properties. Side effects, such as inflammation, acute fibrous formation at the site of injury, toxicity, inability to use in a bloody field, poor physical properties of the sealant, and poor adhesion to the surgical site, can have a serious impact. in the patient and as a result they can play a significant role in the long-term effectiveness of the repair. Also, useful sealants have properties that can make them more effective for surgical application. Features, such as the ability to be located in a specific location, adequately long or short polymerization times, and adequate in vivo resorption characteristics, are vital for a successful completion of the sealing procedure.
[0002] Patent FR-2-754-268 discloses a biocompatible adhesive composition comprising collagen 20 or dissolved gelatin and at least one biodegradable macromolecular polyaldetffdo. Robert et al., "Chemistry for peptide
and rotein PEGylation ", ADVANCED DRUG DELIVERY REVIEWS vol. 54, num. 4, 2002 provides a review of the chemistry of first and second generation PEGylation.
[0003] Thus, there is a continuing need for the development of new biocompatible compositions for use as sealants, as well as for use in other applications.
SUMMARY DESCRIPTION
[0004] Biocompatible protein compositions of invertible phase and methods for making and using them are provided. The invertible phase compositions according to aspects of the invention are prepared
combining a liquid protein substrate and a liquid crosslinking component, wherein the liquid crosslinking component includes a macromolecular crosslinking agent; and wherein said macromolecular crosslinking agent is a reactive product of an excess of a crosslinking agent and a physiologically acceptable polymer selected from a glycosoaminoglycan; and in which the composition undergoes a phase 35 transition from a first fluid state to a second solid state.
[0005] The macromolecular crosslinking agent is produced by combining an excess of a crosslinking agent, for example, a heat treated dialdetffdo, with an amount of a physiologically acceptable polymer, such as a glycosoaminoglycan. The excess of crosslinking agent and the physiologically poffmero
Acceptable react to produce a macromolecular crosslinking agent. When the macromolecular crosslinking agent is combined with the protein substrate, the macromolecular crosslinking agent reacts with the proteins in the substrate component to produce a final composition characterized by the presence of an interpenetrating network.
[0006] Equipment is also provided for use in the preparation of the compositions in question. The compositions in question, equipment and systems find use in a variety of different applications.
BRIEF DESCRIPTION OF THE FIGURE
50 [0007] FIG. 1 provides a table of observed results with different sealant compositions, as described in the Experimental Section, below.
DETAILED DESCRIPTION
[0008] Biocompatible protein compositions of invertible phase and methods for making and using them are provided. The reversible phase compositions in question are prepared by combining a liquid protein substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent; and wherein said macromolecular crosslinking agent is a reactive product of an excess of a crosslinking agent and a physiologically acceptable polymer selected from a
glycosoaminoglycan; and in which the composition undergoes a phase transition from a first liquid state to a second solid state.
[0009] Equipment is also provided for use in the preparation of the compositions in question. The 5 compositions in question, equipment and systems find use in a variety of different applications.
[00010] Before the present invention is described in greater detail, it should be understood that this invention is not limited to particular embodiments described, so it can, of course, vary. It should also be understood that the terminology used in this document is only for the purpose of describing embodiments
10 individuals, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
When a range of values is provided, it is understood that each intermediate value, up to the tenth part of the unit of the lower limit, unless the context clearly dictates otherwise, between the upper limit and the lower limit of that interval and any other indicated or intermediate value in that indicated interval, are included in the invention. The upper and lower limits of these smaller intervals may be included independently in the smaller intervals and are also included in the invention, subject to any limit specifically excluded in the indicated interval. When the indicated interval includes one or both limits, the intervals that exclude one or both of these included limits are also included in the invention.
[0011] Certain intervals are presented in this document with numerical values preceded by the term "approximately". The term "approximately" is used in this document to provide literal support for the exact number that precedes, as well as a number that is close to or is approximately the number that the term precedes. In determining whether a number is near or is approximately a specifically indicated number, the next or approximately non-indicated number may be a number that, in the context in which it is presented, provides the substantial equivalent of the specifically indicated number.
[0012] Unless otherwise defined, all the technical and scientific terms used in this document have the same meaning as that usually understood by an expert in the field to which the invention belongs. Although any procedure and material similar or equivalent to those described in this document is
30 may also be used in the practice or evaluation of the present invention, representative procedures and illustrative materials are described below.
[0013] It should be noted that, as used herein and in the appended claims, the singular forms "a", "a" and "the" include plural referents, unless the context dictates clearly what
35 opposite. It should also be noted that the claims may be written to exclude any optional element. Therefore, this statement is intended as an antecedent basis for the use of exclusive terminology, such as "only", "only" and the like in connection with the mention of the elements of the claims, or the use of a "negative" limitation.
[0014] As will be apparent to those skilled in the art when reading this disclosure, each of the individual embodiments described and illustrated herein have separate and characteristic components that can be easily separated from or combined with the characteristics of any of the other various embodiments without departing from the scope of the present invention. Any mentioned procedure can be carried out in the order of events mentioned or in any other order that is logically possible.
Four. Five
[0015] In further describing the invention in question, the invertible phase compositions according to the invention are first described in greater detail, followed by a review of applications in which the compositions find use, as well as a review of the equipment. and the systems that find use in making or using the invertible phase compositions in question.
fifty
BIOCOMPATIBLE PROTEIC COMPOSITION OF INVERTIBLE PHASE
[0016] As summarized above, the invention in question provides a biocompatible protein composition of invertible phase. The composition, over time, experiences a phase inversion of a
55 first liquid state to a second solid state. In the first liquid state, the invertible phase composition has a sufficient viscosity such that it can be made to flow through a medical cannula or spray on a target tissue site. The invertible phase compositions are characterized by being able to bond tissue in both wet (eg, blood) and dry environments, where the adhesion of the composition to the tissue is exceptionally strong. One aspect of the compositions is that, once they are applied to a location of
target tissue, remain in the location of target tissue. An additional aspect of the compositions in question is that they are well tolerated by the body and do not cause a substantial inflammatory response, if any.
[0017] The reversible phase protein compositions in question are prepared by combining or mixing a liquid protein substrate with a liquid crosslinking composition as disclosed in claim 1.
[0018] Each of these components or precursor compositions is now reviewed separately in greater detail.
10
Crosslinking Agent Composition
[0019] As indicated above, the invertible phase composition is produced by combining a liquid protein substrate, as described above, with a liquid crosslinking agent composition that includes a
15 macromolecular crosslinking agent. While the viscosity of the crosslinking component may vary, in certain embodiments it approximates the viscosity of the protein component, expressed in centistokes (cSt) at approximately 25 ° C, ranging from 10 cSt to 150 cSt, from 30 cSt to 70 cSt. The crosslinking component may be sterilized according to any convenient protocol, where the sterilization protocols of interest include, but are not limited to: gamma, electron beam, and the like. The crosslinking component
20 liquid is stable during storage. By stable during storage it is meant that the substrate
it can be kept under storage conditions, such as at room temperature for a period of
time of at least 1 year or more, such as 3 years or more, without undergoing any substantial change that negatively impacts the function of the substrate in such a way that it is no longer suitable for use in the preparation of a biocompatible composition of invertible phase of the invention
25
[0020] The crosslinking component is produced by combining an excess of a crosslinking agent with an amount of a physiologically acceptable polymer. Examples of crosslinking agents include, but are not limited to: photo-oxidative molecules; carbodiimides; carbonyl-containing compounds, for example, mono- and dicarbonyls, including carboxylic acids, for example, dicarboxylic acids, such as adipic acid, glutaric acid and
30 similar, and aldetndos, including mono- and dialdetndos, for example glutaraldetndo; etc. In certain ways of
embodiment, the crosslinking agent employed is an aldetndo crosslinking agent. In certain of these ways of
embodiment, the aldehyde crosslinking agent is pretreated to produce a stabilized aldetndo crosslinking agent, for example, a stabilized glutaraldetndo crosslinking agent, for example, where the crosslinking agent is thermally stabilized aldetndo, as a thermally stabilized glutaraldetend (as described in the Patent
35 American num. 7,303,757).
[0021] While the amount of crosslinking agent in the composition may vary, in certain embodiments the amount of crosslinking agent ranges between 0.1 and 20% (v / v), such as 0.5 to 15% (v / v) and including 1 to 10% (v / v).
40
[0022] In addition to the crosslinking agent, the crosslinking composition further includes an amount of a physiologically acceptable polymer. The physiologically acceptable polymer can be any polymer that is tolerated by the body and reacts with the crosslinking agent to produce a prepolymeric macromolecular crosslinking product. The prepolymeric product is a reactive product between the crosslinking agent and the
Polymer, and includes a polymeric skeleton with one or more crosslinking molecules covalently bonded thereto such that the polymeric skeleton includes one or more crosslinking functional groups, where the crosslinking functional groups include at least one reactive half, for example, a half of aldetndo, which can be covalently attached to the protein component of the protein substrate. Thus, the prepolymeric product retains the ability to crosslink upon contact with the protein substrate. The prepolymeric product of
Certain embodiments are a soluble macromolecule comprising a molecule of the polymeric skeleton bound to molecules of the crosslinking agent, where at least a portion of the molecules of the crosslinking agent bound retain a half of free crosslinking that can bind protections on the substrate protein This "macromolecular" crosslinking agent of the prepolymeric product may vary in average molecular weight, and in certain embodiments it may range in weight between 10,000 and 4 million Daltons, such as 500,000 to 2
55 million Daltons.
[0023] In certain embodiments, the physiologically acceptable polymer is a glycosoaminoglycan (ie, a mucopolysaccharide). Specific glycosaminoglycans of interest include, but are not limited to: chondroitin sulfate; dermatan sulfate; queratan sulfate; tieparin; tieparan sulfate; e thialuronan (i.e. acid
hyaluronic). In certain embodiments, the glycosoaminoglycan component is hyaluronan.
[0024] The crosslinking agent is present in the excess crosslinking composition with respect to the amount of physiologically acceptable amount. In certain embodiments, the amount of polymer
Physiologically acceptable constitutes up to 0.01 to 5% (w / v), as 0.05 to 3% (w / v) including 0.1 to 1% (w / v) of the crosslinking composition.
[0025] In certain embodiments, the crosslinking agent composition may further include an amount of a viscosity modifying agent. Viscosity modifying agents of interest include,
10 but are not limited to: polyoxyethylene or polyoxypropylene polymers or copolymers thereof, such as polyethylene glycol and polypropylene glycol; non-ionic cellulose ethers such as methyl cellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, carboxy ethyl cellulose and hydroxypropyl cellulose; additional celluloses, such as sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl starch; and the like In certain embodiments of particular interest, the emulsifying agent is a cellulose ether, particularly a non-ionic cellulose ether, such as carboxymethyl cellulose. Carboxymethylcellulose is available in a variety of commercial sources, including but not limited to Sigma, Hercules, Fluka and Noviant. In certain embodiments, the average molecular weight of the cellulose ether is at least about 1000 Daltons, such as at least 5000 Daltons, where the average molecular weight can be as high as 10,000 Daltons or greater, for example, of 50,000 Daltons or greater, 100,000 Daltons or greater, and ranges in certain embodiments from about 5,000 to about 100,000 Daltons, such as about 10,000 to about 50,000 Daltons. The proportion of the viscosity modifying agent in the sealant in certain embodiments ranges from 0.01 to 10% (v / v), such as 0.1 to 4% (v / v) including 0.5 at 2% (v / v).
Protein Substrate 25
[0026] The liquid protein substrate from which the reversible phase compositions in question are prepared is a liquid composition, for example, an aqueous composition, which is composed of at least one protein component and, in certain embodiments, a adhesion modifier, where the substrate may include one or more additional components, including, but not limited to: a plasticizer; a carbohydrate; Y
30 similar.
[0027] The substrate can be sterilized in accordance with any convenient protocol, where the sterilization protocols of interest include, but are not limited to: gamma radiation, electron beam and the like.
[0028] The liquid protein substrate is stable during storage. By stable during storage it is meant that the substrate can be kept under storage conditions, such as at room temperature for a period of at least 1 year or more, such as 3 years or more, without undergoing any substantial change that impacts negatively in the function of the substrate in such a way that it is no longer suitable for use in the preparation of a biocompatible reversible phase composition of the invention. 40
Protein component
[0029] The protein component (ie, protein material) of the substrate is composed of one or more different proteins. The proteins of this component can be synthetic proteins or that are produced from
Naturally, where the proteins can be obtained / prepared using any convenient protocol, for example, purification from sources that occur naturally, recombinant production, synthetic production, and the like, where in certain embodiments the proteins are obtained from sources that occur naturally, for example, bovine, swine or human. Specific proteins of interest include, but are not limited to: albumines, collagen, elastins, fibrins, and the like.
fifty
[0030] The amount of protein in the substrate composition may vary, where the selection of specific concentration depends on the desired application and the desired product parameters, as well as the characteristics of toughness, hardness, elasticity, resorption and the effects of platelet aggregation. In certain embodiments, the total concentration of total proteins in the substrate compositions ranges
Approximately 1 to 75% (w / w), such as 1-50% (w / w), including 5 to 40% (w / w).
[0031] In certain embodiments, the primary protein of the substrate composition of this embodiment is albumin, where the albumin may be a naturally occurring albumin, for example, human albumin, bovine albumin, porcine albumin etc., or a variant thereof. As it is known in the
technically, albumin can be purchased as a powder and then dissolved in an aqueous suspension, or alternatively, it can be purchased in aqueous form. The purified albumin can be derived from any one of a number of different sources including, bovine, ovine, equine, human, or avian according to well known procedures (ref .: Cohn et al, J. Amer. Chem. Soc. 69 : 1753) or can be purchased in purified form from a supplier, such as Aldrich Chemical (St. Louis, Missouri), in lyophilized or aqueous form. Albumin can be derivatized to act as a carrier for drugs such as heparin sulfate, growth factors, antibiotics, or it can be modified in an effort to moderate viscosity, or hydrophilicity. Derivatization using acetylating agents, such as, but not limited to, sucrose anhydride, and lauryl chlorides, are useful for the production of binding sites for the addition of useful molecules. In these embodiments where the protein component includes albumin, albumin may be present in concentrations ranging from about 10 to about 50% (w / w), such as from about 30 to about 40% (w / w).
[0032] In certain embodiments, the protein component also includes a collagen, for example, a naturally occurring collagen (human, bovine, porcine) or a synthetic variant thereof. From
According to the invention, collagen can be in dry or aqueous forms when mixed with albumin. Collagen can be derivatized to increase its usefulness. It has been proven that acetylating agents, such as anhydrated or acid chlorides, produce useful places for the union of molecules such as growth factors, and antibiotics. When present, the collagen sometimes ranges from about 1 to about 20 20% (w / w), including from about 1 to about 10% (w / w), such as from about 1 to about 4 % (w / w), including 2 to 4% (w / w) approximately.
[0033] The protein component in question, as described above, may or may not include one or more active agents, for example, drugs, present in it, as desired. When present, the agent (s) will
25 can / n bind the polymers, as desired.
Adherent agent
[0034] Also present may be one or more adherent agents. The bonding agents improve the adhesion of the sealant to the biological surface. In many embodiments, adhesion modifiers
they are polymeric compounds that have charged functions, for example, amines, etc. While numerous adherent agents can be used, one of particular applicability is polyethyleneimine (PEI). PEI is a branched, long chain alkyl polymer containing primary, secondary and tertiary amines. The presence of these highly ionic groups results in significant coupling through ionic interactions with the underlying surface. In addition, the presence of PE1 in the substrate significantly increases the presence of suitable terminal amines to produce crosslinks with the crosslinking agent. Additional adherent agents of interest include, but are not limited to: gelatin, carboxymethyl cellulose, butylhydroxytoluene, chitosan, etc.
[0035] In certain embodiments of the invention, adherent agents are used to modify the adhesion to the biological substrate while simultaneously creating a procoagulant. In certain embodiments, the bonding agents are present in concentrations of from about 0.1 to about 10% (w / w), such as from about 0.1 to about 4% (w / w).
45 Optional Components
[0036] The substrate component described above of the compositions in question may, in certain embodiments, include one or more optional components that modify the properties of the invertible phase composition produced from the substrate and the crosslinking agent. Optional components representative of
50 interests are now analyzed in greater detail below.
Plasticizing agents
[0037] According to the invention, a plasticizing agent may be present in the substrate. The plasticizing agent 55 provides a number of functions, including wetting a surface, or shape
alternatively, increase the elastic modulus of the material, or even more, help in the mixing and application of the material. There are numerous plasticizing agents, including fatty acids, for example, oleic acid, palmic acid, etc., dioctyl phthalate, phospholipids, and phosphatidic acid. Since plasticizers are usually organic substances not soluble in water and not easily miscible with water, sometimes it is advantageous to modify their miscibility
with water, previously mixing the appropriate plasticizer with an alcohol to reduce the surface tension associated with the solution. For this purpose, any alcohol can be used. In a representative embodiment of this invention, oleic acid is mixed with ethanol to form a 50% solution (w / w) and this solution is then used to plasticize the protein substrate during the formulation process. While the type and concentration of the plasticizing agent depend on the application, in certain embodiments the final concentration of the plasticizing agent is about 0.01% (w / w), including about 2 to about 2. 4% (w / w). Other plasticizing agents of interest include, but are not limited to: polyethylene glycol, glycerin, butylhydroxytoluene, etc.
10 Procoagulant carbohydrate
[0038] In certain embodiments, the substrates include a procoagulant carbohydrate. Chitosan and chitosan derivatives are potent blood coagulators and, therefore, are beneficial in the formulation of sealant materials capable of sealing vascular lesions. While it has been proven that practically
All chitin materials have some procoagulant activity, according to the invention, the use of acetylated chitin is used as an additive for the formulation of sealant intended for blood control. Acetylation of the molecule can be achieved in a number of different ways, but a common procedure is the treatment of chitosan / acetic acid mixtures with acid anhydrides, such as sucdnic. This reaction is easily carried out at room temperature. In accordance with the invention, gels created in this manner in combination with protein substrates and cross-linked in situ are beneficial for the creation of a biocomposite structural member. Thus, the procoagulant carbohydrate can be chitosan, low molecular weight chitosan, chitin, chitosan oligosaccharides, and chitosan derivatives thereof. According to the teachings of this invention the carbohydrate component, for example, chitosan, may be present in concentrations ranging from about 0 to about 20%, such as from about 0.1 to about 5% (w / w).
Stuffed
[0039] Fillers of interest include both reinforcing and non-reinforcing fillers. Reinforcing fillers may be included, such as chopped fibrous silk, polyester, PTFE, NAILON, carbon fibers, polypropylene, polyurethane, glass,
etc. The fibers can be modified, for example, as described above for the other components, as desired, for example, to increase wettability, miscibility, etc. Reinforcing fillers may be present at about 0 to 40%, such as about 10 to about 30%. Non-reinforcing fillers may also be included, for example, clay, mica, hydroxyapatite, calcium sulfate, bone chips, etc. 35 Where desired, these fillers can also be modified, for example, as described above. Non-reinforcing fillers may be present at about 0 to 40%, such as about 10 to about 30%.
Biologically Active Agents 40
[0040] Biologically active agents may be included, for example, bone growth factors, tissue activators, cartilage growth activators, small molecule active agents, etc. Thus, biologically active agents can include, peptides, polypeptides, proteins, saccharides, polysaccharides and carbohydrates, nucleic acids, and organic and inorganic materials of small molecules. Agents
Specific biologically active agents include antibiotics, antivirals, steroidal and non-steroidal anti-inflammatories, antineoplasics, antispasmodics including channel blockers, modulators of cell interactions with the extracellular matrix including cell growth inhibitors and anti-adhesion molecules, enzymes and enzyme inhibitors , anticoagulants, growth factors, DNA, RNA and protein synthesis inhibitors, agents against cell migration, vasodilators, and other drugs used for the treatment of tissue injury. Examples of these compounds include angiotensin converting enzyme inhibitors, antithrombotic agents, prostacyclin, heparin, salicylates, thrombodotic agents, antiproliferative agents, nitrates, calcium channel blocking drugs, streptokinase, urokinase, tissue plasminogen activator (TPA) and acylated plasminogen activator (PA) and acylated streptokinase-plasminogen activator complex (APSAC), colchicine, and alkylating agents, growth modulating factors such as interleukins, growth factor P transformation and platelet derived growth factors, Monoclonal antibodies directed against growth factors, modified extracellular matrix components or their receptors, lipid and cholesterol sequestrants and other agents that can modulate vascular tone, function, arteriosclerosis, and the healing response to vessel or vessel injury Organ after the intervention.
Foaming agent
[0041] In certain embodiments, the substrate may include a foaming agent which, when combined with the crosslinking agent composition, results in a foamed composition, for example, a composition 5 that includes gaseous air bubbles interspersed everywhere. . Any convenient foaming agent may be present, where the foaming agent may be an agent that, upon contacting the crosslinking composition, produces a gas that provides a generation of bubbles and, therefore, the desired foaming characteristics of the composition. . For example, a salt such as sodium bicarbonate in an amount ranging from about 2 to about 5% w / w may be present in the substrate.
When the substrate is combined with an acidic crosslinking agent composition, for example, having a pH of approximately 5, a foamed composition is produced.
Additional modifiers
[0042] Additional modifiers may also be present. For example, mixtures of one or more polymers (for example, polymixes), such as Teflon, PET, NAILON, hydrogels, polypropylene, etc. may be present. Polyezclas can be modified, for example, as described above, to ensure the desired properties. These additional modifiers may be present in amounts ranging from about 0 to 50%, including from about 10 to about 30%.
twenty
Shock absorber
[0043] When the protein substrate and the crosslinking agent are mixed to produce the invertible phase composition in question, the damping of the invertible phase composition is employed in certain embodiments by a
25 number of reasons, for example, to optimize the bond strength of the composition to the coupling surface, to optimize the conditions necessary for internal crosslinking to occur, etc. For example, optimal crosslinking for proteins using glutaraldetute crosslinking agents occurs in a pH range of about 6 to about 8. Buffers capable of maintaining this range are useful in this invention, as long as they do not interfere with the terminal carbonyl of the crosslinking agent
30 or modify the amino terminus of the amino acids. For example, phosphate buffers have a pKa value in the pH 7.0 range and do not interfere with the crosslinking process since they do not contain carboxylic or ammic functions. The phosphate buffer of a resistance of up to 1 M is suitable for use as a buffer in the present invention, where in certain embodiments the phosphate buffer has a resistance of about 0.01 to about 0.3M. While phosphate buffering of
35 solutions is ideal for protein substrate stability in applications where increased adhesion is required, an acidic buffer can also be used. It has been found that 0.1-1M citrate buffers and that they have a pH range of about 4.5 to about 6.5 are useful for this invention.
[0044] The buffer may be present in the initial crosslinking agent component or in the initial protein substrate component, or present in both components, as desired.
Combination of substrate and crosslinking agent to produce the invertible phase composition
[0045] As summarized above, the reversible phase compositions in question are prepared by combining a liquid protein substrate and a liquid crosslinking agent in appropriate amounts and under conditions sufficient for the reversible phase composition to occur. In certain embodiments, the substrate and the crosslinking agent are combined in a ratio (v / v) ranging from approximately 1/5 to approximately 5/1; so that a resulting invertible phase composition is produced in which the total concentration of
50 proteins range from about 10 to about 60%, from about 20% to about 50%, including from about 30 to about 40% and the total crosslinking agent composition ranges from about 0.1 to about 20%, such as about 0.5 to about 15%, including about 1 to about 10%.
[0046] The combination of the substrate and the crosslinking agent usually occurs under mixing conditions, such that the two liquid components are combined or completely mixed with each other. The combination or mixing can be carried out using any convenient protocol, for example, by manually combining two components, using a device that combines the two components, etc. The combination or mixing is usually carried out at a temperature ranging from about 20
and about 40 ° C, as at room temperature.
[0047] The combination of the protein substrate and the crosslinking agent as described above results in the production of an invertible phase composition. By composition of invertible phase is meant a
5 composition that goes from a first liquid state to a second solid state. In the second solid state, the composition is substantially, if not completely, incapable of fluid flow. The invertible phase composition usually remains in a solid state, after the combination of the substrate components and the crosslinking agent, for a period of time ranging from approximately 10 seconds to approximately 10 minutes, such as approximately 20 seconds to 5 seconds. Approximately minutes, including approximately 30 to about 120 seconds, when maintained at a temperature ranging from approximately 15 ° C to approximately 40 ° C, such as approximately 20 ° C to approximately 30 ° C.
[0048] Specific invertible phase formulations include as components: (i) a first composition 15 comprising a protein substrate composition having approximately 30% -50% albumin, and chloride
of approximately 0.1% -0.3% chitosan; and (ii) a second composition comprising a cross-linking composition having approximately 3% -10% heat treated glutaraldehyde, approximately 0.1% -1% hyaluronic acid, and optionally, 0% -1.5 sodium salt Approximately% carboxymethyl cellulose high viscosity. Such invertible phase formulations generally have an average cure time of approximately 5-60 seconds after the first and second compositions are added and mixed, and an average breakage of approximately 125-1000 mmHg, and more commonly, an average cure time of Approximately 10-30 seconds, and an average break of approximately 200-850 mmHg, as measured at room temperature approximately.
[0049] In a particular embodiment, an invertible phase formulation is provided which includes as components: (i) a first composition comprising a protein substrate composition having approximately 40% albumin, and 0 chitosan chloride , Approximately 2%; and (ii) a second composition comprising a crosslinking composition having approximately 4.4% -7.5% heat treated glutaraldehyde, approximately 0.2% hyaluronic acid, and optionally, 0% -0 sodium salt, Approximately 75% of high viscosity carboxymethylcellulose. Such invertible phase formulations generally have an average cure time of approximately 10-30 seconds when the first and second compositions are added and mixed, and an average breakage of approximately 250-800 mmHg, and more commonly, an average cure time of 10 -15 seconds approximately, and an average breakage of approximately 350-700 mmHg, as measured at room temperature approximately.
35
[0050] As also described above, various additional materials may be incorporated into the invertible phase compositions to serve any of the various purposes, such as to modify the physical characteristics of the composition, and / or assist in the repair of a tissue. or objective biological material to which the composition is applied. For example, biologically active agents such as peptides can be incorporated,
40 proteins, nucleic acids, carbohydrate molecules, small molecules and the like to attract and bind specific cell types, such as white blood cells and platelets, or materials such as fibronectin, vimentin, and collagen, can be used to increase healing through a non-binding specific. Tracking material, such as barium, iodine or salts thereof, can also be included to allow visualization and / or monitoring of the invertible phase composition. In certain embodiments, different biologically active agents can be used in different applications or layers when one or more invertible phase compositions are applied differentially.
[0051] In certain embodiments, cells can also be incorporated into or applied in connection with the invertible phase compositions before, during and / or after application of the composition. When used, cells are generally included in the protein substrate composition, or applied in conjunction
50 with or separately from the invertible phase composition in a manner that allows its adhesion at the place of application. The cells can be live, artificial cells, ghosts of cells (i.e., ghosts of red blood cells or platelets), or pseudovirions, depending on a given end use. For example, cells can be selected to produce specific agents as growth factors at the site of application. Biologically active agents that modulate viability, differentiation, and / or cell growth can also be included. In some embodiments, the cells may be stem cells, or in other embodiments, progenitor cells that correspond to the type of tissue at the location of the treatment or other cells, which provide therapeutic advantages. For example, liver cells incorporated into the invertible phase composition and applied to a wound or liver surface of a patient can help regeneration and repair. This can be particularly useful in cases where diseases such as cirrhosis, fibrosis, chronic disease or
Cancer results in non-functional tissue, scar formation or tissue replacement with cancer cells. Similar procedures can be applied to other organs and tissues as well.
[0052] Biologically active agents can be incorporated physically and / or by chemical coupling. The physical incorporation is carried out by mixing the biologically active agent with the phase material
invertible before and / or during application to the target surface and healing. The material is usually mixed in the protein substrate solution to form a solution, suspension or dispersion. In one embodiment, the biologically active agent can be encapsulated within administration devices such as microspheres, microcapsules, liposomes, cell ghosts or pseudovirions, which in themselves affect the rates of release and absorption by the cells. The chemical incorporation of the biologically active agent is carried out by chemically coupling the agent to a polymeric material of the protein substrate or of the cross-linking composition, usually of the protein substrate, before or at the time of polymerization (for example, by conjugation through reactive functional groups, such as aminos, hydroxyls, thiols, and the like). To ensure that the desired cure times and breakage properties of the invertible phase composition 15 are maintained, the physical and / or chemical incorporation of a biologically active agent takes into account the relative amounts of protein substrate and crosslinking agent present in the final composition, and can be adjusted accordingly.
PROCEDURES
twenty
[0053] The biocompatible compositions of the invertible phase in question are used in procedures in which an amount of the invertible phase composition is administered to a particular place or location of a subject, patient or guest in need thereof. The subject, patient or host is usually a "mairnfero" or "Mammalia", where these terms are widely used to describe organisms that are within the
25 Mammalia class, including, but not limited to, carnivora orders (e.g. dogs and cats), rodents (e.g., mice, guinea pigs, and rats), lagomorphs (e.g. rabbits) and primates (e.g. , humans, chimpanzees, and monkeys). In many embodiments, the animals or guests, that is, the subjects (also referred to herein as patients) will be human.
[0054] The amount administered to the subject in any given application will necessarily vary depending on the nature of the application and the use of the composition, but in certain representative embodiments it ranges from about 1 to about 50 ml, as of about 1 to about 25 ml, including about 1 to about 5 ml, for example, about 3 ml.
35
[0055] While it necessarily depends on the particular application in which the composition in question is being used, the composition in question, in many embodiments, is administered locally to a particular region, place or location of the host, where the place or location may, of course, vary. Representative locations or locations include, but are not limited to: vessels, organs, and the like. Depending on the
In particular application, the composition can be administered to the place of interest manually or with an administration device, for example, the administration device used to administer the composition in stent implant applications, described in greater detail below.
UTILITY
Four. Five
[0056] The biocompatible compositions of the invertible phase in question find use in a variety of different applications. Representative applications of the invertible phase compositions in question include those described in US Pat. Nos. 3,438,374; 5,092,841; 5,292,362; 5,385,606; 5,575,815; 5,583,114; 5,843,156; 6,162,241; 6,290,729; 6,302,898; 6,310,036; 6,329,337; 6,371,975; 6,372,229; 6,423,333;
50 6,458,147; 6,475,182; 6,547,806; and 7,303,757; as well as US applications nums. 2002/0015724; 2002/0022588; 2002/0133193; 2002/0173770; 2002/0183244; 2002/019490; 2002/0032143.
SYSTEMS
55 [0057] Systems are also provided for the practical use of the procedures in question. The systems may include fluid administration elements for the administration of the substrate composition and cross-linking to the site of administration, mixing elements, etc. Examples of such systems include those described in U.S. Patent No. 7,303,757.
EQUIPMENT
[0058] Equipment is also provided for use in practice of the procedures in question, where the equipment usually includes components of a composition other than liquid substrate and liquid cross-linking of a reversible phase fluid composition, as described above. . The substrate and crosslinking compositions may be present in separate containers in the equipment, for example, where the substrate is present in a first container and the crosslinking agent is present in a second container, where the containers may or may not be present in A combined configuration.
[0059] The equipment in question may also include a mixing device, for mixing the substrate and the crosslinking agent with each other to produce the invertible phase composition. The equipment may also include an administration device (which may or may not include a mixing element), such as a double-cylinder syringe, catheter devices, and the like, as described above.
[0060] The equipment may also include other components, for example, GMA wires, sensor cables, etc., that may find use in the practice of the procedures in question.
[0061] In addition to the aforementioned components, the equipment in question usually also includes instructions for using the equipment components to implement the procedures in question.
20 The instructions for implementing the procedures in question are generally recorded in an appropriate means of registration. For example, instructions can be printed on a substrate, such as paper or plastic, etc. Thus, the instructions may be present in the equipment as a leaflet, in the labeling of the equipment container or the components thereof (that is, associated with the smallest package or package included in it) etc. In other embodiments, the instructions are present as an electronic storage data file 25 present in a suitable computer-readable storage medium, for example, CD-ROM, floppy disk, etc. In other embodiments, the instructions themselves are not present in the equipment, but means are provided to obtain the instructions from a remote source, for example through the internet. An example of this embodiment is a device that includes an internet address in which the instructions can be viewed and / or from which the instructions can be downloaded. As with the 30 instructions, this means of obtaining the instructions is recorded on a suitable substrate.
[0062] The following examples are provided by way of illustration and not by way of limitation.
EXPERIMENTAL
35
[0063] Various formulations of invertible phase compositions were prepared in which the sodium salt of hyaluronic acid (AH) was included in the protein component and the crosslinking component. Illustrative formulations were tested as shown in Table 1.
40 Table 1
 Lot#  Protein formulation Crosslinking formulation
 Alb  AH Cl Quit 213 GATT AH CMC high vis
 004-49  40% 0.0% 0.2% 7.5% 0.2% 0.00%
 004-42-1  40% 0.2% 0.2% 4.4% 0.0% 0.75%
 004-42-2  40% 0.2% 0.2% 7.5% 0.0% 0.75%
 004-42-3  40% 0.2% 0.2% 4.4% 0.0% 0.00%
 003-118-2  40% 0.0% 0.2% 7.5% 0.2% 0.75%
Abbreviations: Alb = Albumina; AH = hyaluronic acid; Cl Quit 213 = Chitosan Chloride; GATT = heat treated glutaraldehyde; and CMC high vis = sodium salt of high viscosity carboxymethylcellulose _____________________
The protein solution is prepared in a 10mM phosphate buffer solution, pH 6.2. The crosslinking agent solution is prepared in a 10mM phosphate buffer solution, pH 7.
An in vitro test system was used to determine the breaking strength of each formulation. A 45 square inch portion of a porcine aortic wall is secured to a pressure vessel over a hole with a diameter of 5 mm. A hole is drilled through the aorta using a 14 gauge needle. The sealant is applied to the aorta over the 14 gauge needle hole and allowed to cure. An air pressure is applied to the interior of the pressure vessel until the sealant is broken. The air pressure required to cause the rupture is measured using a manometer.
[0064] The observed properties of these formulations are shown in tabular form in FIG. 1, and in Table 2, for the aorta test system.
Table 2
 Lot#  Average cure time (sec) n = 2 Average break (mmHg) n = 2
 004-49  19.50 565.20
 004-42-1  22.00 353.70
 004-42-2  13.50 566.20
 004-42-3  33.50 246.20
 003-118-2  11.50 499.20
5
[0065] The results in FIG. 1 and Table 2 demonstrate that when hyaluronic acid (AH) is provided in the crosslinking component and not in the protein component, unwanted interactions with the protein component are eliminated and the viscosity of the crosslinking component is increased, which one gives
10 resulted in an improved 2-component global sealant composition.
[0066] Although the preceding invention has been described in some detail by way of illustration and example for the sake of clarity of understanding, it is readily apparent to those with basic knowledge in the field in accordance with the teachings of this invention that certain changes and modifications to it without
15 deviate from the spirit or scope of the appended claims.
[0067] Thus, the foregoing simply illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various provisions that, although not described or shown explicitly in this document, embody the principles of the invention and are included within their scope. Likewise, all
20 examples and the conditional language mentioned in this document are primarily intended to help the reader understand the principles of the invention and the concepts contributed by the inventors to promote the technique, and should be interpreted to be without limitation for such examples and conditions specifically mentioned.

权利要求:
Claims (8)
[1]
I. An invertible phase composition produced by combining:
5 (a) a liquid protein substrate, and
(b) an liquid crosslinking composition comprising a macromolecular crosslinking agent; Y
wherein said macromolecular crosslinking agent is a reactive product of an excess of a crosslinking agent and a physiologically acceptable polymer selected from a glycosoaminoglycan; Y
in which the composition undergoes a phase transition from a first liquid state to a second solid state.
15 2. The invertible phase composition according to claim 1, wherein said
glycosoaminoglycan is hyaluronan.
[3]
3. The invertible phase composition according to any one of the preceding claims, wherein said liquid protein substrate comprises a protein material selected from the group consisting of:
20 albumin, elastin, fibrin and soluble and insoluble collagen forms and combinations thereof.
[4]
4. The invertible phase composition according to any one of the preceding claims, wherein said protein substrate further comprises at least one of an adherent agent, a plasticizer, and a carbohydrate.
25
[5]
5. The invertible phase composition according to any one of the preceding claims, wherein said crosslinking agent comprises an aldetute, such as glutaraldetute, wherein said glutaraldetute is optionally thermally stabilized.
30 6. A process of producing an invertible phase composition, combining said procedure:
(a) a liquid protein substrate; Y
(b) a liquid crosslinking composition comprising a macromolecular crosslinking agent;
35
to produce said invertible phase composition; Y
wherein said macromolecular crosslinking agent is a reactive product of an excess of a crosslinking agent and a physiologically acceptable polymer selected from a glycosoaminoglycan; and 40
in which the composition undergoes a phase transition from a first liquid state to a second solid state.
[7]
7. The process according to claim 6, wherein said glycosoaminoglycan is hyaluronan.
[8]
8. The method according to any one of claims 6 or 7, wherein said protein substrate comprises a protein material selected from the group consisting of: albumin, elastin, fibrin and soluble and insoluble collagen forms and combinations thereof .
fifty
[9]
9. The method according to any one of claims 6 to 8, wherein said crosslinking agent comprises an aldehyde, such as glutaraldehyde, wherein said glutaraldehyde is optionally thermally stabilized.
55 10. A solid phase composition produced by the process of any one of the
claims 6 to 9.
II. A device for producing an invertible phase composition, said equipment comprising:
(a) a protein substrate; Y
(b) a crosslinking composition comprising a macromolecular crosslinking agent; Y
5 (c) an invertible phase fluid delivery device; Y
wherein said macromolecular crosslinking agent is a reactive product of an excess of a crosslinking agent and a physiologically acceptable polymer selected from a glycosoaminoglycan; Y
10 in which the composition undergoes a phase transition from a first liquid state to a second solid state.
[12]
12. The equipment according to claim 11, wherein said glycosoaminoglycan is hyaluronan.

类似技术:

---

公开号 | 公开日 | 专利标题

---

EP1545411B1|2018-09-26|Biocompatible phase invertable proteinaceous compostions and methods for making and using the same

---

ES2383550T3|2012-06-22|Quick-acting dry sealant material and methods for use and processing

---

US10675378B2|2020-06-09|Biocompatible phase invertible proteinaceous compositions and methods for making and using the same

---

US10722610B2|2020-07-28|Biocompatible phase invertible proteinaceous compositions and methods for making and using the same

---

BR112013012772B1|2019-05-14|Preparation and / or formulation of polysaccharide crosslinked proteins

---

JP2011505204A5|2011-12-22|

同族专利:

---

公开号 | 公开日

---

HUE025522T2|2016-02-29|

---

US20190255214A1|2019-08-22|

---

US20090143500A1|2009-06-04|

---

US9789221B2|2017-10-17|

---

EP2219555A1|2010-08-25|

---

US20140235825A1|2014-08-21|

---

US10675378B2|2020-06-09|

---

US8198363B2|2012-06-12|

---

US20140041547A1|2014-02-13|

---

US20200297895A1|2020-09-24|

---

US20120222584A1|2012-09-06|

---

US10279073B2|2019-05-07|

---

JP2014012220A|2014-01-23|

---

EP2219555B1|2015-07-08|

---

US8586671B2|2013-11-19|

---

EP2219555A4|2013-01-23|

---

JP5409646B2|2014-02-05|

---

DK2219555T3|2015-08-24|

---

PL2219555T3|2015-12-31|

---

CA2706701A1|2009-06-11|

---

PT2219555E|2015-10-05|

---

WO2009073668A1|2009-06-11|

---

ES2544962T3|2015-09-07|

---

EP2219555B9|2015-12-23|

---

CA2706701C|2016-10-25|

---

JP2011505204A|2011-02-24|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3438374A|1966-02-28|1969-04-15|Us Health Education & Welfare|Method of bonding tissue surfaces and controlling hemorrhaging thereof using a tissue adhesive and hemostatic composition|

---

US4060081A|1975-07-15|1977-11-29|Massachusetts Institute Of Technology|Multilayer membrane useful as synthetic skin|

---

US4448718A|1983-09-13|1984-05-15|Massachusetts Institute Of Technology|Method for the preparation of collagen-glycosaminoglycan composite materials|

---

US5575815A|1988-08-24|1996-11-19|Endoluminal Therapeutics, Inc.|Local polymeric gel therapy|

---

US5843156A|1988-08-24|1998-12-01|Endoluminal Therapeutics, Inc.|Local polymeric gel cellular therapy|

---

US5092841A|1990-05-17|1992-03-03|Wayne State University|Method for treating an arterial wall injured during angioplasty|

---

US5292362A|1990-07-27|1994-03-08|The Trustees Of Columbia University In The City Of New York|Tissue bonding and sealing composition and method of using the same|

---

US5385606A|1992-07-06|1995-01-31|Kowanko; Nicholas|Adhesive composition and method|

---

US6475182B1|1997-03-12|2002-11-05|Olexander Hnojewyj|Fluidic media introduction apparatus|

---

US6302898B1|1994-06-24|2001-10-16|Advanced Closure Systems, Inc.|Devices for sealing punctures in body vessels|

---

US5583114A|1994-07-27|1996-12-10|Minnesota Mining And Manufacturing Company|Adhesive sealant composition|

---

US5817303A|1995-05-05|1998-10-06|Protein Polymer Technologies, Inc.|Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer|

---

FR2754268B1|1996-10-07|1998-12-24|Dev Des Utilisations Du Collag|ADHESIVE COMPOSITION BASED ON MACROMOLECULAR POLYALDEHYDE AND METHOD OF CROSSLINKING COLLAGEN OR GELATIN|

---

ZA987019B|1997-08-06|1999-06-04|Focal Inc|Hemostatic tissue sealants|

---

US20020022588A1|1998-06-23|2002-02-21|James Wilkie|Methods and compositions for sealing tissue leaks|

---

US20020015724A1|1998-08-10|2002-02-07|Chunlin Yang|Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing|

---

US6371975B2|1998-11-06|2002-04-16|Neomend, Inc.|Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers|

---

US6458147B1|1998-11-06|2002-10-01|Neomend, Inc.|Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue|

---

KR20010093810A|1998-12-08|2001-10-29|그래햄 이. 테일러|Mel-bondable polypropylene/ethylene polymer fiber and composition for making the same|

---

US6310036B1|1999-01-09|2001-10-30|Last Chance Tissue Adhesives Corporation|High strength, Bio-compatible tissue adhesive and methods for treating vigorously bleeding surfaces|

---

JP2000288079A|1999-04-07|2000-10-17|Toyobo Co Ltd|Adhesive for biotissue|

---

US6245729B1|1999-07-27|2001-06-12|Ecolab, Inc.|Peracid forming system, peracid forming composition, and methods for making and using|

---

DE60043229D1|1999-09-15|2009-12-10|Cryolife Inc|COMPOSITION FOR VESSEL COATING|

---

US6391048B1|2000-01-05|2002-05-21|Integrated Vascular Systems, Inc.|Integrated vascular device with puncture site closure component and sealant and methods of use|

---

US6547806B1|2000-02-04|2003-04-15|Ni Ding|Vascular sealing device and method of use|

---

US20020173770A1|2001-05-16|2002-11-21|Flory Alan R.|Adhesive delivery system|

---

JP4966494B2|2002-08-06|2012-07-04|マトリックスメディカルエルエルシー|Biocompatible phase-convertible proteinaceous composition and methods for making and using the same|

---

US20040052850A1|2002-09-13|2004-03-18|Kemal Schankereli|Proteinaceous hemostatic tissue sealant|

---

PL2219555T3|2007-12-03|2015-12-31|Tenaxis Medical Inc|Biocompatible phase invertible proteinaceous compositions|PL2219555T3|2007-12-03|2015-12-31|Tenaxis Medical Inc|Biocompatible phase invertible proteinaceous compositions|

---

US9155815B2|2009-04-17|2015-10-13|Tenaxis Medical, Inc.|Biocompatible phase invertible proteinaceous compositions and methods for making and using the same|

---

CN103124633A|2010-08-03|2013-05-29|巴斯夫欧洲公司|Tackifiers for composite articles|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US99186707P| true| 2007-12-03|2007-12-03|

---

US991867P|2007-12-03|

---

PCT/US2008/085283|WO2009073668A1|2007-12-03|2008-12-02|Biocompatible phase invertible proteinaceous compositions|

---